Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

Supportive Care in Cancer

Volumn 14, Issue 10, 2006, Pages 1030-1037

  Fagnoni, Philippe ^a,g   Limat, Samuel ^a,b,c   Chaigneau, Loïc ^d   Guardiola, Emmanuel ^d   Briaud, Stéphanie ^a,d   Schmitt, Bernard ^e   Merrouche, Yacine ^f   Pivot, Xavier ^d   Woronoff Lemsi, Marie Christine ^a,g  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e Public Health Insurance Regional Direction of the Medical Department   (France)

^f Loire Cancer Institute   (France)

^g UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Adjuvant chemotherapy; Breast neoplasms; Cost effectiveness analysis; Erythropo etin; Quality of life

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EPOETIN ALFA; FEMALE; FLUOROURACIL; FRANCE; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33749021388     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0062-5     Document Type: Article

References (29)

1. Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A:S2-S8
2. Baltussen R, Leidl R, Ament A (1999) Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making. PharmacoEconomics 16:449-458
3. Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781-787
4. Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH (2005) The impact of anaemia and its treatment on employee disability and medical costs. PharmacoEconomics 23:183-192
5. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216
6. Cascinu S, Fedeli A, Del Ferro E, Luzi FS, Catalano G (1994) Recombinant human erythropoïetin treatment in cisplatin-associated anaemia: a randomized, double-blind trial with placebo. J Clin Oncol 12:1058-1062
7. Cella D (1998) Factors influencing QOL in cancer patients: anaemia and fatigue. Semin Oncol 25:43-46
8. Chang J, Couture F, Young S, Mc Watters KL, Lau CY (2005) Weekly epoetin alfa maintains haemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597-2605
9. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokahn BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in haemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895
10. Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality adjusted life-years and supportive care. PharmacoEconomics 16:459-472
11. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412-3425
12. Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, Obermair A, Wagner H, Sevelda P (2003) Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 79:347-353
13. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317
14. Fayers P, Hand D (1997) Generalisation from phase III clinical trials: survival, quality of life and health economics. Lancet 350:1025-1027
15. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15:1218-1234
16. Glaspy J, Degos L, Dicato M, Demetri GD (2002) Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinium- and non-platinium-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 7:126-135
17. Gyrd-Hansen D (2005) Willingness to pay for a QALY. Theoretical and methodological issues. PharmacoEconomics 23:423-432
18. Hyland ME (1997) Quality of life measures as providers of information on value for money of health interventions. PharmacoEconomics 11:19-31
19. Leese B, Hutton J, Maynard A (1992) A comparison of the costs and benefits of recombinant human erythropoietin in the treatment of chronic renal failure in 5 European countries. PharmacoEconomics 1:346-356
20. Leonard RC, Untch M, Von Koch F (2005) Management of anaemia in patients with breast cancer: role of epoetin. Ann Oncol 16:817-824
21. Lind M, Vernon C, Cruikshank D, Wilkinson P, Littlewood T, Stuart N, Jenkinson C, Grey -Amante P, Doll H, Wild D (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86:1243-1249
22. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Raport for the Epoetin alfa study group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non platinium chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
23. Ludwig GB, Barnett-Lee P, Krzakowski M (2002) Prevalence and management of anaemia in patient with hematologic malignancies and solid tumors: results from the European Cancer Anaemia Survey. Blood 100:234a-235a, Abstract 884
24. Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, Umek H (1993) Erythropoïetin treatment for chronic anaemia of selected haematological malignancies and solid tumors. Ann Oncol 4:161-167
25. Marchetti M, Barosi G (2004) Clinical and economic impact of epoetins in cancer care. PharmacoEconomics 22:1029-1045
26. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H (1998) Recombinant human erythropoïetin in the treatment of chemotherapy-induced anaemia and prevention of transfusion requirement associated with solid tumors: a randomised controlled study. Ann Oncol 9:255-260
27. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Haematology. J Clin Oncol 20:4083-4107
28. Spaeth D, Casadevall N, Daouphars M, Marchal C, Marec-Berard P, Fabre N, Haugh M (2004) Summary version of the standards, options and recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology-Update 2003. Bull Cancer 91:179-188
29. Whittington R, Barradell LB, Benfield P (1993) Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. PharmacoEconomics 3:45-82